A series of 211 patients with systemic lupus erythematosus (SLE) was presented, 84 of whom had initial renal involvement; 81 of 211 patients were treated with HN2; 130 of 211 patients were not treated with HN2 and tend to assume the role of a control group. Although it is difficult to draw any specific conclusions because of the wide range of variations in patients with SLE, there appears to be a definite and beneficial longterm effect from the use of HN2 in lupus erythematosus (LE) nephropathy.